A5024823969- Cell Adhesion Molecules Research
- Extracellular vesicles in disease
- Prostate Cancer Treatment and Research
- Immunotherapy and Immune Responses
- Cardiac tumors and thrombi
- Venous Thromboembolism Diagnosis and Management
- Receptor Mechanisms and Signaling
- Adrenal and Paraganglionic Tumors
- RNA Research and Splicing
- Neuropeptides and Animal Physiology
Thomas Jefferson University
2019-2024
Sidney Kimmel Cancer Center
2019-2022
The αVβ6 integrin, an epithelial-specific cell surface receptor absent in normal prostate and expressed during cancer (PrCa) progression, is a therapeutic target many cancers. Here, we report that transcript levels of ITGB6 (encoding the β6 integrin subunit) are significantly increased metastatic castrate-resistant androgen receptor-negative tumors compared to receptor-positive tumors. In addition, protein elevated PrCa patient derived xenografts (PDXs) PDXs. vitro, cells express high cells....
The β1 integrins, known to promote cancer progression, are abundant in extracellular vesicles (EVs). We investigated whether prostate (PrCa) EVs affect anchorage-independent growth and integrins required for this effect. Specifically using a cell-line-based genetic rescue an vivo PrCa model, we show that gradient-purified small (sEVs) from either cells or blood tumor-bearing TRAMP (transgenic adenocarcinoma of the mouse prostate) mice cells. In contrast, sEVs cultured harboring short hairpin...
Abstract It is known that small extracellular vesicles (sEVs) are released from cancer cells and contribute to progression via crosstalk with recipient cells. We have previously reported sEVs expressing the αVβ3 integrin, a protein upregulated in aggressive neuroendocrine prostate (NEPrCa), differentiation (NED) Here, we examine impact of expression on sEV content, density function. used this study were isolated by iodixanol gradients characterized nanoparticle tracking analysis,...
Highly aggressive, metastatic, neuroendocrine prostate cancer, which typically develops from cancer cells acquiring resistance to androgen deprivation therapy, is associated with limited treatment options and hence poor prognosis. We have previously demonstrated that the αVβ3 integrin over-expressed in cancer. now show LM609, a monoclonal antibody specifically targets human integrin, hinders growth of patient-derived xenografts vivo. Our group has recently identified novel binding partner,...
Abstract Androgen deprivation therapies aimed to target prostate cancer (PrCa) are only partially successful given the occurrence of neuroendocrine PrCa (NEPrCa), a highly aggressive and metastatic form PrCa, for which there is no effective therapeutic approach. Our group has demonstrated that while absent in adenocarcinoma, αVβ3 integrin expression increased during progression toward NEPrCa. Here, we show novel pathway activated by promotes NE differentiation (NED). This requires GPI-linked...